This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's New Reveal LINQ ICM Gets FDA 510(k) Clearance
by Zacks Equity Research
Medical device major, Medtronic plc (MDT) recently received the U.S. FDA 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection.
Medtronic's Pacemaker Business Wins CMS Coverage Approval
by Zacks Equity Research
Medtronic plc (MDT) recently won the U.S. CMS coverage approval for its Micra Transcatheter Pacing System (TPS).
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
by Zacks Equity Research
Medtronic plc (MDT) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon for treatment of peripheral arterial disease (PAD).
Medtronic (MDT) Presents 5-Year Cost Data of CRT Devices
by Zacks Equity Research
Medtronic plc (MDT) recently presented a five-year data report on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division.
Medtronic Poised on Strong Fundamentals Despite Several Woes
by Zacks Equity Research
On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View
by Zacks Equity Research
Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.
Medtronic (MDT) Beats on Q3 Earnings & Revenues Estimates
by Zacks Equity Research
Medtronic posted impressive third quarter 2017 results with both earnings and sales beating the Zacks Consensus Estimate.
MedTech Stocks Earnings Slated on Feb 21: MDT, HSIC and More
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 21.
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.
Medtronic (MDT) Adds New Tools, Expands Coronary Suite
by Zacks Equity Research
Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.
Top Research Reports for J&J, Barclays and P&G
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Barclays (BCS), and Procter & Gamble (PG).
United Therapeutics' PAH Suite Bodes Well, Competition Rife
by Zacks Equity Research
On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
Medtronic Teams Up with Fitbit, Accelerates Diabetic Care
by Zacks Equity Research
Medtronic recently joined forces with Fitbit (FIT) to create an integrated diabetes care management program.
Medtronic Endurant II/IIs Stent Graft System Wins CE Mark
by Zacks Equity Research
Medtronic plc (MDT) recently won CE mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients through a ChEVAR procedure.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
Medtronic Introduces CoreValve Evolut R System in Japan
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of reimbursement approval from MHLW for its transcatheter CoreValve Evolut R System.
Medtronic Stock Falls on Mixed 2Q; Positive on HeartWare Buy
by Zacks Equity Research
On Nov 30, 2016, we issued an updated research report on medical device major, Medtronic plc (MDT).
Medtronic Partners UH to Launch Integrated Health Solutions
by Zacks Equity Research
Medtronic plc (MDT) recently announced the signing of its Integrated Health Solutions agreement with University Hospitals (UH) in the U.S.
MedTech Industry Stock Outlook - December 2016
by Zacks Equity Research
The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.
Medtronic's Less-Invasive HVAD Implant System Gets CE Mark
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of CE mark for its HVAD System left ventricular assist device (LVAD) for patients with advanced heart failure.
Company News for November 23, 2016
by Zacks Equity Research
Companies In The News are: CPB,DPS,MDT,PANW